Federation des caisses Desjardins du Quebec’s Corcept Therapeutics CORT Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,323	Closed	-$255K	–	2990
2025 Q4	$255K	Buy	7,323 +1,073	+17%	+$84.3K	﹤0.01%	1459
2025 Q3	$519K	Buy	+6,250	New	+$452K	﹤0.01%	1219
2020 Q2	–	Sell	-4,192	Closed	-$50.4K	–	2141
2020 Q1	$50.4K	Buy	+4,192	New	+$51.9K	﹤0.01%	1252
2019 Q2	–	Sell	-23,995	Closed	-$282K	–	2275
2019 Q1	$282K	Buy	23,995 +23,830	+14,442%	+$296K	﹤0.01%	880
2018 Q4	$2.2K	Hold	165	–	–	﹤0.01%	1904
2018 Q3	$2.31K	Sell	165 -3,870	-96%	-$54.1K	﹤0.01%	1981
2018 Q2	$63.4K	Sell	4,035 -26,202	-87%	-$456K	﹤0.01%	1297
2018 Q1	$498K	Sell	30,237 -26,925	-47%	-$499K	0.01%	747
2017 Q4	$1.03M	Sell	57,162 -2,235	-4%	-$40.5K	0.02%	628
2017 Q3	$1.15M	Buy	+59,397	New	+$886K	0.02%	586

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's CORT Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 7,323 shares — an estimated $255K sold.

Federation des caisses Desjardins du Quebec first reported a position in CORT in Q3 2017 and held it in 10 quarters. The position peaked at $1.15M in Q3 2017. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Federation des caisses Desjardins du Quebec reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 7,323 Corcept Therapeutics shares in Q1 2026, an estimated $255K.
Federation des caisses Desjardins du Quebec first reported a position in Corcept Therapeutics in Q3 2017 and held it in 10 quarters.
Federation des caisses Desjardins du Quebec's Corcept Therapeutics position peaked at $1.15M in Q3 2017.
351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.